Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
ANUH PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ANUH PHARMA Mar-23 |
ADCOCK INGRAM Jun-14 |
ANUH PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 110 | 325 | - | |
Low | Rs | 77 | 234 | - | |
Sales per share (Unadj.) | Rs | 105.3 | 96.6 | - | |
Earnings per share (Unadj.) | Rs | 7.2 | -24.3 | - | |
Cash flow per share (Unadj.) | Rs | 9.2 | -20.2 | - | |
Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
Avg Dividend yield | % | 2.1 | 0 | - | |
Book value per share (Unadj.) | Rs | 48.1 | 75.8 | - | |
Shares outstanding (eoy) | m | 50.11 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.9 | 2.9 | 30.7% | |
Avg P/E ratio | x | 12.9 | -11.5 | -112.7% | |
P/CF ratio (eoy) | x | 10.2 | -13.9 | -73.7% | |
Price / Book Value ratio | x | 1.9 | 3.7 | 52.7% | |
Dividend payout | % | 27.7 | 0 | - | |
Avg Mkt Cap | Rs m | 4,683 | 47,183 | 9.9% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 172 | 2,961 | 5.8% | |
Avg. sales/employee | Rs Th | 0 | 3,798.6 | - | |
Avg. wages/employee | Rs Th | 0 | 689.8 | - | |
Avg. net profit/employee | Rs Th | 0 | -957.2 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5,275 | 16,307 | 32.3% | |
Other income | Rs m | 61 | 114 | 53.5% | |
Total revenues | Rs m | 5,336 | 16,421 | 32.5% | |
Gross profit | Rs m | 518 | -2,826 | -18.3% | |
Depreciation | Rs m | 97 | 704 | 13.8% | |
Interest | Rs m | 7 | 442 | 1.7% | |
Profit before tax | Rs m | 475 | -3,857 | -12.3% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 113 | 241 | 46.8% | |
Profit after tax | Rs m | 362 | -4,109 | -8.8% | |
Gross profit margin | % | 9.8 | -17.3 | -56.7% | |
Effective tax rate | % | 23.8 | -6.2 | -380.7% | |
Net profit margin | % | 6.9 | -25.2 | -27.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,076 | 11,944 | 25.8% | |
Current liabilities | Rs m | 1,613 | 6,720 | 24.0% | |
Net working cap to sales | % | 27.7 | 32.0 | 86.6% | |
Current ratio | x | 1.9 | 1.8 | 107.3% | |
Inventory Days | Days | 66 | 111 | 59.2% | |
Debtors Days | Days | 1,185 | 124 | 956.0% | |
Net fixed assets | Rs m | 966 | 6,962 | 13.9% | |
Share capital | Rs m | 251 | 76 | 330.9% | |
Net worth | Rs m | 2,412 | 12,799 | 18.8% | |
Long term debt | Rs m | 0 | 4,498 | 0.0% | |
Total assets | Rs m | 4,042 | 24,179 | 16.7% | |
Interest coverage | x | 64.6 | -7.7 | -835.9% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 1.3 | 0.7 | 193.5% | |
Return on assets | % | 9.1 | -15.2 | -60.2% | |
Return on equity | % | 15.0 | -32.1 | -46.7% | |
Return on capital | % | 20.0 | -19.8 | -100.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 539 | 1,392 | 38.7% | |
From Investments | Rs m | -435 | -427 | 101.7% | |
From Financial Activity | Rs m | -123 | 4,082 | -3.0% | |
Net Cashflow | Rs m | -19 | 5,047 | -0.4% |
Compare ANUH PHARMA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare ANUH PHARMA With: DISHMAN CARBOGEN AMCIS AMI ORGANICS ALCHEMIST LIMITED BIOCON GLENMARK PHARMA
After opening the day on positive note, Indian share markets reversed the trend as the session progressed and ended lower.